Newsletter
Contact
Careers
Calendar
RFP
Français
myGAVI
Donate
Home
About the Alliance
Learn more about GAVI
GAVI's mission
What we do
GAVI's impact
Challenges and opportunities
Healthy girls, healthy women
Gender and immunisation
Why invest in GAVI?
Advocates
GAVI's strategy
Value of vaccination
GAVI's partnership model
GAVI's business model
Global health and development
Governing GAVI
GAVI Board
GAVI Secretariat
GAVI Internal Audit
Programmatic and Finance Policies
Corporate Policies
Types of support
What GAVI offers and how it works
Apply for support
New and underused vaccines support
Human papillomavirus vaccine
Injection safety support
Measles second dose
Meningitis A vaccine
Pentavalent vaccine
Pneumococcal vaccine
Measles-Rubella vaccine
Rotavirus vaccine
Yellow fever vaccine
Immunisation services support
Health Systems Funding Platform
Health system strengthening
Civil society organisation
Country hub
Afghanistan
Albania
Angola
Armenia
Azerbaijan
Bangladesh
Benin
Bhutan
Bolivia
Bosnia & Herzegovina
Burkina Faso
Burundi
Cambodia
Cameroon
Central African Republic (the)
Chad
China
Comoros
Congo
Congo, DR
Côte d’Ivoire
Cuba
Djibouti
Eritrea
Ethiopia
Gambia
Georgia
Ghana
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
India
Indonesia
Kenya
Kiribati
Korea, DPR
Kyrgyzstan
Lao PDR
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Moldova
Mongolia
Mozambique
Myanmar
Nepal
Nicaragua
Niger
Nigeria
Pakistan
Papua New Guinea
Rwanda
Sao Tome and Principe
Senegal
Sierra Leone
Solomon Islands
Somalia
South Sudan
Sri Lanka
Sudan
Tajikistan
Tanzania, UR
Timor Leste
Togo
Turkmenistan
Uganda
Ukraine
Uzbekistan
Vietnam
Yemen
Zambia
Zimbabwe
Funding & finance
Long-term financial commitments
How GAVI is funded
Key figures: donor contributions & pledges
Donor profiles
Financial reports
GAVI Matching Fund
How it works
Partners
International Finance Facility for Immunisation
Pneumococcal AMC
Results & evidence
Measuring & evaluating performance
Goal-level indicators
Mission indicators
Vaccine goal indicators
Health systems goal indicators
Financing goal indicators
Market-shaping goal indicators
Countries approved for support
Disbursements by country
GAVI's evaluation studies
GAVI first evaluation report
GAVI second evaluation report
GAVI support to CSO evaluation
GAVI-Government of China Hepatitis B vaccination programme
Gender Policy evaluation
IFFIm evaluation
Pneumococcal AMC process and design
Other studies
GAVI Progress reports
Library & news
Search by topic, country and programme
News
Press releases
Statements
Return on investment stories
GAVI features
Eyewitness
GAVI blogs
Audio-visual
Board & committee minutes
GAVI documents
Country documents
Evaluations
Financial reports
Guidelines and forms
Policies
Strategy
Supply and procurement
Publications
Events
You are here:
Library
Audio-visual
Audio-visual
Galleries
Galleries
Bill Gates' G20 Report: why GAVI is ahead of the game
Bill Gates' G20 Report: why GAVI is ahead of the game
in page functions
Bill Gates' report to the G20 summit calls on global leaders to support exactly the kind of innovative approaches to financing development that have become the hallmark of the GAVI business model. Learn more.
03 November 2011
Ben Fisher/GAVI/2011
Bill Gates’ report on financing for development to the leaders of the world's largest economies identifies the G20 as the key body that can bring resources, innovative ideas and leadership for development.
Ryan Youngblood/GAVI/2011
GAVI has been a leading force in innovative finance for development, pioneering three mechanisms to deliver large-scale 'predictable' funds for its immunisation programmes: the International Finance Facility for Immunisation (IFFIm), the Advance Market Commitment (AMC) and, in 2011, the Matching Fund.
IFFIm raises finance by issuing 'vaccine bonds' in capital markets, converting long-term government pledges into immediate cash.
Olivier Asselin/WHO/08
To date, IFFIm has raised over US$ 3.5 billion for GAVI immunisation programmes.
Edy Purnomo/GAVI/07
The AMC accelerates the development and manufacture of vaccines for developing countries at affordable prices.
Riccardo Gangale/GAVI/2011
Thanks to the pneumococcal AMC, affordable pneumococcal vaccines are now available to protect children in developing countries from the leading cause of the world's biggest killer of under-fives: pneumonia. Since 2010, GAVI funding has helped 15 countries introduce pneumococcal vaccine into their national immunisation programmes.
Ben Fisher/GAVI/2011
Through the GAVI Matching Fund, launched in 2011, contributions to GAVI from companies, foundations, their customers, employees and business partners are matched.
The G20 includes 10 GAVI donors and two implementing countries, India and Indonesia. Together, these countries have helped lay the foundation in innovative finance leading to GAVI's success in preventing more than five million future deaths.
Latest Galleries
Launch ceremony for introduction of pentavalent vaccine - Mogadishu, Somalia
Immunisation in Islamic countries
Madagascar celebrates the introduction of pneumococcal vaccines
Brazzaville marks Congo's first pneumococcal vaccinations
Rotavirus vaccines introduced in health centres in Yemen
The human tragedy and the hope behind Ghana’s historic decision
Model immunisation system sets standard for Mozambique
Seth Berkley in Mozambique March 2012
Chad’s campaign against meningitis A
GAVI’s Matching Fund announcement at WEF
View all latest galleries
Search keywords
Bill Gates
G20
innovative finance
IFFIm
AMC
The GAVI Matching Fund
modal window here